All In Biotech

Drug Trial Radar · NCT07474467

Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Split-Face, Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Administration of TRTP-101 in Adults With Atrophic Scars

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

31

Planned (sponsor's estimate)

Start

Aug 12, 2026

Primary completion

Feb 1, 2029

Study completion Aug 1, 2029

Sponsor

Lead sponsor
CellinCellsIndustry
Sponsor type
Industry
First posted
Mar 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial was to evaluate the safety and efficacy of a single administration of TRTP-101 in adults with atrophic scars.

Conditions

  • Atrophic Scar

Interventions

  • TRTP-101Biological

    Intradermal injection

  • PlaceboBiological

    Intradermal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. [Phase 1] Number of Subjects with Dose Limiting ToxicityTime frame: within 4 weeks
  2. [Phase 2] Proportion of subjects achieving ≥ 1-grade improvement from baseline in ASRSTime frame: 12, 24 weeks after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.